Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.
You may also be interested in...
Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.